Tilray (DE:2HQ0)
XETRA:2HQ0
2HQ0 Stock Chart & Stats
€5.71
--
Market closed
€5.71
--
Day’s Range― - ―
52-Week Range€2.81 - €19.88
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.66K
Market Cap
€674.51M
Enterprise Value€899.16M
Total Cash (Recent Filing)€219.93M
Total Debt (Recent Filing)€317.08M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Jul 29, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding116,548,660
10 Day Avg. Volume1,751
30 Day Avg. Volume2,660
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.18
Price to Sales (P/S)0.34
P/FCF Ratio-2.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.83Price Target Upside19.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.41
Revenue Forecast (FY)€744.44M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained top-line expansion and record quarterly revenue indicate the business is scaling across core channels. Durable organic growth improves operating leverage potential, strengthens distribution bargaining power and underpins medium-term cash generation if margins remain stable.
International & Distribution ExpansionRapid international volume growth and expanding pharmacy/distribution footprints diversify revenue and reduce single‑market risk. Deeper market access and higher medical volumes create more predictable, recurring demand and support durable scale benefits over several quarters.
Structural Cost Savings & LiquidityRealized annualized cost reductions and a materially stronger cash position provide lasting improvement to margins and financial flexibility. Lower fixed costs and improved liquidity help absorb integration costs and cyclical headwinds over the medium term.
Bears Say
Persistent GAAP Losses & Negative Cash FlowLarge cumulative losses and ongoing negative free cash flow erode equity and limit self-funding. This structural cash deficit increases reliance on external financing, constrains capital allocation choices and raises solvency risk if profitable operations are not achieved within months.
Beverage Revenue & Margin PressureDeclining beverage sales and compressed gross margins reflect structural challenges: overhead absorption, higher input costs and integration lags. Given beverage is being scaled via acquisitions, prolonged margin recovery could materially limit consolidated profitability over multiple quarters.
Regulatory Uncertainty In U.S. Hemp/CannabisPending regulatory shifts in the U.S. create structural demand and product-design risk for beverage and hemp-derived offerings. Restrictive rules or bans would shrink addressable markets, force reformulations or delistings, and increase long-term compliance costs and strategic uncertainty.
Tilray News
2HQ0 FAQ
What was Tilray’s price range in the past 12 months?
Tilray lowest stock price was €2.81 and its highest was €19.88 in the past 12 months.
What is Tilray’s market cap?
Tilray’s market cap is €674.51M.
When is Tilray’s upcoming earnings report date?
Tilray’s upcoming earnings report date is Jul 29, 2026 which is in 110 days.
How were Tilray’s earnings last quarter?
Tilray released its earnings results on Apr 01, 2026. The company reported -€0.192 earnings per share for the quarter, missing the consensus estimate of -€0.116 by -€0.075.
Is Tilray overvalued?
According to Wall Street analysts Tilray’s price is currently Undervalued.
Does Tilray pay dividends?
Tilray does not currently pay dividends.
What is Tilray’s EPS estimate?
Tilray’s EPS estimate is >-0.01.
How many shares outstanding does Tilray have?
Tilray has 116,548,660 shares outstanding.
What happened to Tilray’s price movement after its last earnings report?
Tilray reported an EPS of -€0.192 in its last earnings report, missing expectations of -€0.116. Following the earnings report the stock price went down -2.394%.
Which hedge fund is a major shareholder of Tilray?
Currently, no hedge funds are holding shares in DE:2HQ0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tilray Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€6.83 (19.67% Upside)
€6.83 (19.67% Upside)
Blogger Sentiment
Neutral
DE:2HQ0 Sentiment 50%
Sector Average ―
Sector Average ―
News Sentiment
Bearish
Bullish news 33%
Bearish news 67%
Bearish news 67%
Technicals
SMA
Negative
20 days / 200 days
Momentum
47.96%
12-Months-Change
Fundamentals
Return on Equity
-92.82%
Trailing 12-Months
Asset Growth
-39.04%
Trailing 12-Months
Company Description
Tilray
Tilray Brands, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. It offers medical and adult-use cannabis products, including GMP-certified flowers, oils, vapes, edibles, and topicals; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. The company offers its products under the Tilray, Aphria, Broken Coast, Symbios, B!NGO, The Batch, P'tite Pof, Dubon, Good Supply, Solei, Chowie Wowie, Canaca, RIFF, SweetWater, Breckenridge Distillery, Alpine Beer Company, and Green Flash brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. Tilray Brands, Inc. is headquartered in Leamington, Canada.
2HQ0 Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted clear operational progress: record quarterly revenue, strong international cannabis momentum, meaningful distribution growth, completed cost-savings programs and strategic beverage partnerships/acquisition that materially expand the company’s scale. Several significant challenges remain — beverage revenue and margin pressure, input cost volatility (aluminum, fuel), working capital-related cash use, regulatory uncertainty in the U.S., and integration work for BrewDog — but management presented concrete actions (hedging, Project 420, SKU rationalization, partnerships) and a strengthened liquidity position. On balance, the positive operational and strategic developments outweigh the near-term headwinds.View all DE:2HQ0 earnings summaries2HQ0 Stock 12 Month Forecast
Average Price Target
€6.83
▲(19.67% Upside)
Options Prices
Currently, No data available
---